A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme.

Trial Profile

A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2011

At a glance

  • Drugs Anti-tenascin monoclonal antibody 81C6 I-131; Temozolomide
  • Indications Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Acronyms GLASS-ART
  • Sponsors Bradmer Pharmaceuticals
  • Most Recent Events

    • 05 Nov 2010 Bradmer suspended enrolment of primary GBM patients in its Phase III multi-center clinical trial of Neuradiab in the first quarter of 2009, according to a media release.
    • 08 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
    • 23 Jul 2008 Status changed to recruiting. Bradmer reports that the first patient was enrolled at Duke University.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top